Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee Contents General Information...............................................................................8 Program-at-a-Glance...........................................................................10 Agenda........................................................................................................11 Abstract Index.........................................................................................18 Funding for this conference was made possible [in part] by Grant Number 5U54MD007593-08 from the National Institute on Minority Health and Health Disparities (NIMHD) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the NIH; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. The current MeTRC grant supports health disparities and translational research on HIV/AIDS, cancer, cardiovascular diseases, diabetes, and neurological disorders. Join us on Social Media with #MeharryTRC! We teach health caring. Our medical, dental, and research graduates answer the call to serve, so that our vision for the future nurtures a healthier America—eliminating health disparities, achieving health equity. healthcaring.mmc.edu Meharry Medical College • 1005 Dr. D.B. Todd Jr. Blvd. • Nashville, TN 37208 • www.mmc.edu A United Methodist Church-related institution Addressing He Translational Research Center (MeTRC) The Role of Translatio #MeharryTRC | November 10–11 Addressing Health Dispari Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennesse The purpose of the Meharry Clinical and Translational Research Center (MeTRC) grant is to cultivate minority researchers by funding their projects, and building an infrastructure of laboratories, training, and support staff. Budding scientists compete for pilot projects, in hopes their research ideas will mature into collaborative projects with other investigators. In time, they become fully funded researchers who are able to attract external funding and operate independently. Translational research is a branch of scientific research that has developed in recent years which translates lab discoveries into actual treatments patients can use. The scientists in the Meharry Translational Research Center look for treatments for diseases and health disorders that disproportionately impact minorities. Areas of emphasis include infectious diseases (especially HIV/AIDS) and women’s health. Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee Dear Conference Attendee: The Meharry Medical College Translational Research Center (MeTRC) welcomes you to our inaugural health disparities conference Addressing Health Disparities: The Role of Translational Research and to Nashville. The MeTRC Health Disparities Conference is developed to bring together investigators, trainees and community groups to engage an educational and informational exchange around the important translational research resources that contribute to improved health outcomes and a better quality of life. This program presents opportunities for discussion on the regional impact of disparities research in cancer, infectious diseases including HIV/AIDS, cardiovascular diseases, diabetes, and neurological disorders in the clinical, basic science, and population health areas. It will also focus on the roles of translational research in addressing health disparities in these diseases. Our keynote speakers, key experts, blue ribbon and poster presenters were selected to heighten the national discussion on the importance of research, particularly as it regards improvement in minority health and health disparities research. As program chair, I want to thank all of those who contributed to creating this inaugural conference and recognizing the importance of this activity as we look to integrate basic science, clinical science and community engagement around the translational efforts of research to improve health outcomes. Furthermore, I want to express our gratitude to our session co-chairs, key expert, and keynote speakers. To each of you, the planning committee thanks you for your attendance and participation. We look forward to your feedback. Sincerely, Samuel E. Adunyah, PhD Professor and Distinguished Chairman Biochemistry and Cancer Biology PI/PD, Meharry Clinical Translational Research Ctr. PI, MMC-VICC-TSU Cancer Partnership NCI Grant GENERAL INFORMATION Meharry Translational Research Center (MeTRC), along with our partners, host this one and one-half day conference, titled Addressing Health Disparities: The Role of Translational Research, to focus on the regional impact of disparities research in cancer, infectious diseases including HIV/ AIDS, cardiovascular diseases, diabetes, and neurological disorders in the clinical, basic science, and population health areas. The conference features plenary sessions, professional development activities, and poster presentations around the key translational research areas. Meharry Medical College is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. The goals of the MeTRC Health Disparities conference are to: 1. Provide a forum for researchers and experts in health disparities research to share their work in traditionally underserved, racial, and ethnic groups; Disclosure The Meharry Medical College adheres to ACCME Essential Areas, Standards, and policies regarding industry support of continuing medical education. Disclosure of the planning committee and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations. 2. Enhance professional development in areas of team building, collaborations and partnerships, and grant writing as well as provide meaningful networking and collaboration opportunities; 3. Promote minority researchers conducting basic, clinical, and socialbehavioral translational research to eliminate health disparities; and 4. Increase awareness of Meharry clinical and translational research and MeTRC. LEARNING OBJECTIVES At the end of this activity, participants will be able to: 1. Describe translational research methods utilized in the study of the science of health disparities and intervention in the areas of HIV/ AIDS, Cardiovascular Disease and Diabetes, and Cancer; and 2. Explain the importance of translational and community-engaged research in addressing specific diseases of disparities. Credit Designation Meharry Medical College designates this educational activity for a maximum of 10.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Resolution of Conflicts of Interest In accordance with the ACCME Standards for Commercial Support of CME, the Meharry Medical College Office of Lifelong Learning has implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity. Disclaimer The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. PLANNING COMMITTEE Program Chair Samuel E. Adunyah, PhD MeTRC PI/PD – Meharry Medical College ACCREDITATION Meharry Medical College, School of Dentistry, is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. Members-at-Large Ketia Barnes Program Coordinator – Meharry Medical College Allyson Flemming, EdD Director, Lifelong Learning – Meharry Medical College Elizabeth Gottlieb-Meade Senior Administrative Assistant – Meharry Medical College Meharry Medical Colleges designates this live continuing dental education lecture and hands-on program for continuing education credits. L. Denise Holland, MA Program Coordinator – Meharry Medical College Concerns or complaints about a CE provider may be directed to the provider or to ADA CERP at www.ada.org/cerp. Kermit G. Payne, BFA Conference Organizer – 1Joshua Group, LLC Sandra Settles, PA CME Program Coordinator – Meharry Medical College Karen Smith Senior Administrative Assistant – Meharry Medical College Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee GENERAL INFORMATION BADGES SOCIAL MEDIA STUDENT POSTER COMPETITION FUNDING Badges and conference materials are distributed upon check-in. Badges are required to access conference sessions, and can be replaced at $50 each. The 2016 Student Poster Competition is designed to encourage and acknowledge students and junior investigators whose research contributes to addressing health disparities and translational research. Competition Eligibility Requirements Accepted abstracts that were submitted by Students, Post-Docs, and Faculty Members identified as the first author on the Abstract Submission Form will be considered for the Student Poster Competition. All entrants must be in an accredited program and/or institution and designated as a student, post-doc, or faculty at the time of submission. Recognition of Participants and Winners The award will acknowledge a recipient in each of four categories: undergraduate, graduate, doctoral, and post-doctoral. Awardees will be announced during the Summary & Adjournment session. SPEAKER READY HOURS 2nd Floor • Room 210 Please post about your experiences at the MeTRC Health Disparities Conference on social media sites using the hash tag #MeharryTRC. Funding for this conference was made possible [in part] by Grant Number 5U54MD007593-08 from the National Institute on Minority Health and Health Disparities (NIMHD) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the NIH; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. The current MeTRC grant supports health disparities and translational research on HIV/AIDS, cancer, cardiovascular diseases, diabetes, and neurological disorders. SECRETARIAT 1Joshua Group, LLC www.The1JoshuaGroup.com 404.559.6191 Thursday......................8:00 AM – 3:00 PM Friday.........................7:00 AM – 10:00 AM SPONSOR This activity is sponsored by the Meharry Medical College Translational Research Center (MeTRC). COMMUNITY EXHIBITORS MeTRC would like to acknowledge the following Community Exhibitors: Beckman Coulter BioTek Instruments Meharry Sickle Cell Center Morehouse School of Medicine Tennessee State University University of Hawaii Biorepository Vanderbilt University Medical Center VWR 9 PROGRAM-AT-A-GLANCE THURSDAY, NOVEMBER 10th Continental Breakfast 7:00 AM 7:30 AM 8:00 AM Continental Breakfast 10:30 AM 11:00 AM Room 201 GENERAL SESSION III Auditorium 9:00 AM 10:00 AM Ballroom A Meet the Experts Ballroom A 8:30 AM 9:30 AM FRIDAY, NOVEMBER 11th PROFESSIONAL DEVELOPMENT ACTIVITIES Auditorium GENERAL SESSION IV Auditorium 11:30 AM 12:00 PM 12:30 PM Lunch Ballroom A 1:00 PM 1:30 PM 2:00 PM 2:30 PM Scientific Network Session & Lunch Ballroom GENERAL SESSION I Auditorium SUMMARY & CLOSING Ballroom A 3:00 PM 3:30 PM 4:00 PM 4:30 PM GENERAL SESSION II Auditorium 5:00 PM 5:30 PM 6:00 PM 6:30 PM 7:00 PM 7:30 PM Join us on Social Media with Poster Networking Session & Dinner Ballroom #MeharryTRC! AGENDA THURSDAY, NOVEMBER 10, 2016 9:00 AM – 12:00 PM PROFESSIONAL DEVELOPMENT ACTIVITIES Location: Auditorium Professional development is critical to the successful path of understanding the current research environment, preparing applications across research disciplines, securing funding for research, and creating the appropriate research team. This session will investigate strategies around these areas and provide information about the current and future landscape. At the end of this session, participants should be able to: • Describe current NIH research opportunities; and • Identify critical areas for successful research funding acquisition and project completion. Opening and Overview Duane T. Smoot, MD Grant Writing Marjorie P. Piechowski, PhD Janet Southerland, DDS, PhD, MPH NIH/NIMHD Update Rina Das, PhD Chair and Professor, Department of Internal Medicine Meharry Medical College Professor, Oral Maxillofacial Surgery Meharry Medical College Team Building / Collaboration Kevin Osteen, PhD Adjunct Professor, Obstetrics and Gynecology at Meharry Medical College Pierre Soupart Chair in Obstetrics and Gynecology Professor of Pathology, Microbiology and Immunology Vanderbilt University School of Medicine Kevin G. Osteen, PhD Dr. Osteen is a member of the team that launched the first in vitro fertilization (IVF) program in Tennessee and the fourth program in the United States. He is currently the director of the Women’s Reproductive Health Research Center which includes the International Endometriosis Association Research Program at Vanderbilt. Osteen is an active member of several professional societies and maintains an active research program funded by the National Institutes of Health (NIH), the Environmental Protection Agency (EPA), the Veterans Administration (VA) and Industry contracts and private foundations; frequently served on NIH study sections and as an adviser to biotechnology and pharmaceutical companies. He has authored more than 100 original scientific papers and is a frequent invited speaker. Dr. Osteen’s research program currently focuses on environmental endocrine disruptors in the pathophysiology of infertility and pregnancy failure. Working with Dr. Kaylon Bruner-Tran, their combined research interests include the role of early life exposure to environmental toxicants. Recent research studies have identified inflammation during the preconception period as being an important factor in not only disrupting both male and female fertility but also limiting the capacity of progesterone to support maternal-fetal communication that is necessary for term delivery. Marjorie Piechowski, PhD Dr. Marjorie Piechowski, Director Emerita of Research Support in the College of Engineering & Applied Science at the University of Wisconsin-Milwaukee, has 30 years of experience in grant development and research administration. Earlier positions included Grant Information Specialist at Marquette University (3 years) and Director of Sponsored Programs and Research at DePaul University (17 years). In her most recent position she coordinated and wrote large-scale, collaborative grant applications and facilitated individual faculty research proposals to hundreds of federal, state, private and industry Emerita Director of Research Support University of Wisconsin-Milwaukee Program Officer, Office of Research Training and Capacity Building (ORTCB) Division of Scientific Programs National Institute on Minority Health and Health Disparities Biomedical Informatics and Data Research Paul A. Harris, PhD Professor of Biomedical Informatics Research Professor of Biomedical Engineering Vanderbilt University School of Medicine sponsors. She also conducts proposal development workshops at colleges and universities across the United States and frequently presents on proposal development at research administration conferences. Rina Das, PhD Dr. Rina Das joined NIMHD in July 2014 as a new program officer for the Common Fund Diversity Program. Prior to joining NIMHD, Dr. Das was the Acting Chief of the Disparities Research Branch in the NCI Center to Reduce Cancer Health Disparities. Paul A. Harris, PhD Paul A. Harris, PhD, is professor of biomedical informatics and biomedical engineering who has approximately 20 years’ experience working in the field of clinical research informatics. Dr. Harris earned his doctorate in Biomedical Engineering from Vanderbilt University in 1996 and now serves as Director for Vanderbilt’s Office of Research Informatics. Dr. Harris devised and created REDCap, a research data collection and management software platform that has seen widespread adoption by 2,029 academic and non-profit institutions in 107 countries. He also created and runs a national program designed to ‘match’ volunteers wishing to volunteer for studies and scientists recruiting participants for research at any CTSA institution. The ResearchMatch program is currently serving 102,859 volunteers and 4,165 researchers across 128 academic institutions. 11 AGENDA THURSDAY, NOVEMBER 10, 2016 1:00 PM – 3:30 PM GENERAL SESSION I: Welcome and Opening Location: Auditorium Health disparities in many diseases including HIV/AIDS, cancer, cardiovascular and diabetes remain major health challenge in this country. Strategies to understand the underlying basis of the disparities as well as develop strategies to address them remain the main focus of the National Institute of Minority Health and Health Disparities (NIMHD) of NIH. This session will provide information about the overarching goal of the current Meharry RCTR (MeTRC) Program, and examine the implications of HIV as a disparity across translational platforms including basic science, clinical environments, and population science based applications. At the end of this session, participants should be able to: • Discuss the goals and achievements of the Meharry Medical College Translational Research Center (MeTRC); • Explain the benefits MeTRC collaborations and partnerships; • Discuss the implications of HIV health disparities translational research; and • Explain information about the NIH Clinical Center and its HIV programs. Welcome & Overview of Meharry Translational Research Center (MeTRC) Samuel E. Adunyah, PhD Chair and Professor, Department of Biochemistry and Cancer Biology PI/PD, Meharry Translational Research Center (MeTRC) PI, MMC-VICC-TSU Cancer Partnership NCI Grant Meharry Medical College Conference Keynote Speaker James E.K. Hildreth, PhD, MD President Meharry Medical College HIV Translational and Health Disparities Key Experts Victoria Cargill, MD, MSCE Director of Minority Research and Clinical Studies, Office of AIDS Research National Institutes of Health Session Chairs Fernando Villalta, PhD Chair and Professor, Department of Microbiology and Immunology Meharry Medical College Chandravanu Dash, PhD David Haas, MD, MS Professor of Pathology, Microbiology and Immunology Professor of Pharmacology Vanderbilt University School of Medicine Associate Professor, Department of Biochemistry and Cancer Biology Center for AIDS Health Disparities Research (CAHDR) Meharry Medical College James E.K. Hildreth, PhD, MD James E.K. Hildreth, PhD, MD of Camden, Arkansas began his undergraduate studies at Harvard University and was selected as the first African-American Rhodes Scholar from Arkansas in 1978. He graduated from Harvard magna cum laude in chemistry in 1979. That fall, Dr. Hildreth enrolled at Oxford University in England, graduating with a Doctor of Philosophy in immunology in 1982. At Oxford, he studied the biology of cytotoxic T cells with Sir Andrew McMichael and became an expert in monoclonal antibody technology and cell adhesion molecules. In 1987, he obtained his Doctor of Medicine from Johns Hopkins and joined the Hopkins faculty as assistant professor. In 2002, Dr. Hildreth became the first African American in the 125-year history of Johns Hopkins School of Medicine to earn full professorship with tenure in the basic sciences. In July 2005, Dr. Hildreth became director of the NIH-funded Center for AIDS Health Disparities Research at Meharry Medical College. In October 2008, he was honored for his contributions to medical science by election to the Institute of Medicine, part of the National Academy of Sciences. In August of 2011, Dr. Hildreth became dean of the College of Biological Sciences at University of California, Davis. He was the first AfricanAmerican dean in the university founded in 1905. On July 1, 2015, Dr. Hildreth returned to Meharry Medical College to serve as the 12th president and chief executive officer of the nation’s largest private, independent historically black academic health sciences center. Victoria Cargill, MD, MSCE In 1998 Dr. Cargill was recruited to the NIH after serving as a co-investigator at the NIH funded Case Western AIDS Clinical Trials Unit, and achieved the rank of Professor of Medicine, the second African American woman in the history of the medical school to do so. The author of numerous scientific articles as well as perspective commentaries and analytical essays, she has appeared on local and national programs, such as Morning Edition of National Public Radio, and in popular magazines such as Ebony and Newsweek. In addition to teaching at the University of Pennsylvania Robert Wood Johnson Scholars program, she continues to care for people living with HIV infection in Southeast DC. A member of numerous editorial boards and medical associations, she has named as one of America’s Top Physicians consistently for the past nine years. David Haas, MD, MS David Haas, MD is Professor of Medicine, Pharmacology, Pathology, Microbiology & Immunology at Vanderbilt University School of Medicine, and Adjunct Professor of Internal Medicine at Meharry Medical College. He is also a board certified infectious diseases specialist. His research focuses on human pharmacogenomics relevant to HIV infection and its therapy, including co-infection with tuberculosis. He has led the design and implementation of numerous HIV clinical trials. His focus is on understanding the impact of human genetics on drug efficacy, toxicity, pharmacokinetics, and drug-drug interactions, and translating this into clinical practice. Since 2000 he has led the pharmacogenomics program of the NIH-funded AIDS Clinical Trials Group. His work has included the seminal observation that a frequent CYP2B6 polymorphism predicts delayed clearance of efavirenz, which largely explains increased plasma exposure among individuals of African descent. Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee AGENDA THURSDAY, NOVEMBER 10, 2016 3:45 PM – 5:30 PM GENERAL SESSION II: Diabetes and Cardiovascular Diseases Location: Auditorium Cardiovascular disease and diabetes often exist as comorbid conditions. Difference in these diseases exist with disparity within populations by ethnicity and gender. This session will present information to include the genesis of the diseases, their relationship to each other and as independent factors, and provide opportunity to create improved research, treatment, and lifestyle outcomes. At the end of this session, participants should be able to: • Discuss the current direction of population-based research in diabetes and cardiovascular disease; and • Provide the epidemiological and biostatistical significance of diabetes and CVD as a framework for treatment and research. Session Chairs Stephania Miller-Hughes, PhD Associate Professor, Department of Surgery Meharry Medical College Margaret K. Hargreaves, PhD Professor, Department of Internal Medicine Meharry Medical College Key Experts William J. Blot, PhD Associate Director for Population-Based Research Professor of Medicine (Epidemiology) Cancer Epidemiologist Vanderbilt University School of Medicine James Hebért, ScD Director, Epidemiology and Biostatistics The Cancer Prevention and Control Program University of South Carolina Leonard Egede, MD, MS Allen H. Johnson Endowed Chair Professor of Medicine Director, Center for Health Disparities Research Medical University of South Carolina William J. Blot, PhD William J. Blot, PhD, is Associate Director for Populationbased Research at the Vanderbilt-Ingram Cancer Center, Ingram Professor of Cancer Research in the Department of Medicine, Vanderbilt University Medical Center (VUMC), and Chief Executive Officer of the International Epidemiology Institute (IEI). Prior to co-founding IEI in 1994 and joining VUMC in 2000, Dr. Blot directed research into the causes of cancer for 20 years at the National Cancer Institute. Dr. Blot’s research has yielded key information regarding the distribution, determinants and means of prevention of human cancers. Dr. Blot is principal investigator and designer of the ongoing Southern Community Cohort Study (SCCS), a landmark investigation undertaken to assess the causes of cancer and other chronic diseases among southerners and determinants of racial disparities in health. Findings from this cohort of 86,000 adults, twothirds African American, have already documented multiple demographic, lifestyle and biologic factors that may contribute to racial differences in risk and outcome of cancer, diabetes, cardiovascular and other diseases. James Hebért, ScD Dr. James Hebert is a Health Sciences Distinguished Professor at the University of South Carolina, as well as a Professor in the Department of Epidemiology and Biostatistics, a Professor of Epidemiology at the Medical University of South Carolina, a Professor of Community Medicine and Epidemiology at the University of South Carolina, School of Medicine, and the Director of the Cancer Prevention and Control Program. He received his AB in biology from Boston University in 1971, his diploma in international education from the University of California, Berkeley, in 1979, his MSPH in environmental health from the University of Washington in 1980 and his ScD in nutritional epidemiology from Harvard University in 1984. Leonard Egede, MD, MS Dr. Egede, a general internist, is a tenured Professor and Allen H. Johnson Endowed Chair in the Division of General Internal Medicine and Geriatrics at the Medical University of South Carolina (MUSC). Dr. Egede is also the Director of the MUSC Center for Health Disparities Research and Director of the Charleston VA Health Equity and Rural Outreach Innovation Center, one of 19 VA Health Services Research and Development Centers of Innovation in the nation. Dr. Egede has a M.S. in clinical research and completed a fellowship in health services research. Dr. Egede has led research projects designed to understand the interplay between socio-demographic and psychological factors in health outcomes and test behavioral interventions to reduce health disparities. Dr. Egede is currently funded for the following research projects: 1) PI of a VA HSR&D funded Center grant (HX001229; 10/1/13-9/30/21) to improve access and equity in healthcare for all Veterans; 2) PI of an NIH/ NIDDK R01 (R01DK098529; 5/05/13-04/30/17), an RCT to test the efficacy of a technology-intensified diabetes education/skills training (TIDES) intervention in AAs with poorly controlled T2DM; 3) PI of an NIDDK T35 (T35 DK007431; 5/01/81-04/30/20) to provide short-term research training experience for 24 medical students annually in NIDDK-focused areas; 4) PI of an NIDDK K24 (K24DK093699), which provides protected time for mentoring; and 5) PI of a state (SC) funded grant (04/01/14-03/31/18) to disseminate an effective technology-assisted case management intervention for type 2 diabetes across hospitals/clinics in rural South Carolina. He has authored over 220 original publications in peer-reviewed journals. He was a standing member of the NIH scientific review study section – the Dissemination and Implementation Research in Health Study Section and a member of the National Advisory Council of the Robert Wood Johnson Physician Faculty Scholars Program for several years. He currently is Deputy Editor for the Journal of General Internal Medicine. Dr. Egede is also a board member of the Diabetes Initiative of South Carolina. 13 AGENDA FRIDAY, NOVEMBER 11, 2016 7:00 AM – 8:00 AM BREAKFAST WITH THE EXPERTS: Networking Meet-the-Experts Session Location: Room 201 Meet the experts is an open session driven by active participation. The aim of this session is to provide an informal atmosphere where trainees can interact with experts who will give their undivided attention for half an hour over breakfast, for knowledge, career development, and networking. Key Experts Lucile L. Adams-Campbell, PhD Associate Director, Minority Health & Health Disparities Research Professor of Oncology, Lombardi Comprehensive Cancer Center Georgetown University Medical Center Rick A. Kittles, PhD Director, Division of Population Genetics Center for Applied Genetics and Genomic Medicine Professor, Cancer Biology, GIDP University of Arizona College of Medicine Beti Thompson, PhD Professor, Health Services Fred Hutchinson Cancer Research Center Steven F. Wakefield HIV Vaccine Trials Network External Relations Director Fred Hutchinson Cancer Research Center Isaac Powell, MD Professor, Department o fUrology Wayne State University ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee AGENDA FRIDAY, NOVEMBER 11, 2016 8:00 AM – 10:00 AM GENERAL SESSION III: Community and Population-Based Studies Model Location: Auditorium Population-based study models examine a broad selection of potential risk factors for improving health outcomes through collaborations and various network constructs. This session will explore the success of community approaches to reduce cancer, HIV, and other health disparities in minority and other underserved populations. At the end of this session, participants should be able to: • Discuss successful, long-termed implementation and evidence-based strategies to create community approaches in population-based studies;and • Describe effective communications to eliminate the mistrust factor of clinical trials in minority communities. Session Chairs Charles P. Mouton, MD, MS Key Experts Beti Thompson, PhD Consuelo Wilkins, MD, MSCI Steven F. Wakefield Professor, Department of Family and Community Medicine Meharry Medical College Executive Director, Meharry-Vanderbilt Alliance Associate Professor of Medicine Vanderbilt University School of Medicine Professor, Health Services Fred Hutchinson Cancer Research Center HIV Vaccine Trials Network External Relations Director Fred Hutchinson Cancer Research Center Beti Thompson, PhD Dr. Beti Thompson is a member of the Public Health Sciences Division of the Fred Hutchinson Cancer Research Center. Much of Dr. Thompson’s previous and current work focuses on the Latino population, with a specific emphasis on cancer prevention and cancer screening for breast, cervical, and colorectal cancers. Dr. Thompson’s focus on health disparities research is exemplified by a number of projects, including “Hispanic Community Network to Reduce Cancer Disparities” and “Partnership for a Hispanic Diabetes Prevention Program.” Both of these projects take place in the Yakima Valley of Washington State. The projects work with local Community Advisory Boards to guide and lead the activities to reduce health disparities of cancer and diabetes. Steven F. Wakefield Steve Wakefield is the External Relations Director for the NIH-funded HIV Vaccine Trials Network at Fred Hutchinson Cancer Research Center and leads global efforts for stakeholder engagement. Wakefield (preferred name) is also founder of The Legacy Project, HVTN’s program to increase racial and ethnic population involvement in trials. Wakefield currently serves on the AVAC: Global HIV Prevention Board. Wakefield is an HIV-negative health care advocate with over thirty years of involvement in projects that increase community participation in HIV prevention research and ethics. With thirtyfive plus years of non-profit management, public service on Chicago’s Board of Health, global and U.S. federal advisory groups such as WHO’s UNAIDS, he is excited about this current time for implementation of evidence based strategies to end the HIV/AIDS epidemic. 15 AGENDA FRIDAY, NOVEMBER 11, 2016 10:00 AM – 12:15 PM GENERAL SESSION IV: Cancer Model Location: Auditorium According to the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the American Cancer Society (ACS), the overall incidence and death rates of the major types of cancer including colon cancer, breast cancer, and prostate cancer have fallen significantly within the last thirty years. However, significant differences exist in both the incidence and death rates among the various ethnic/ racial groups whereby African Americans have the highest rates involving cancers of breast, colon, lung, and prostate among the various ethnic/racial groups in the nation. Also, geographic disparities exist regarding cancer incidence and death rates whereby the Southeastern states appear to have th highest incidence and death rates in some common types of cancer. Furthermore, other factors, including comorbidities, access to care, education, behavioral modification, and diet impact on effectiveness of cancer prevention and control. This session will examine some of the current data related to the disparities, and discuss the underlying factors including biological, epigenetics, and socioeconomic factors attributing to the cancer health disparities as well as strategies to address them. At the end of this session, participants should be able to: • Discuss the underlying factors of cancer health disparities; and • Describe the impact of translational research in narrowing the health disparities gap. Session Chairs Samuel E. Adunyah, PhD Chair and Professor, Department of Biochemistry and Cancer Biology PI/PD, Meharry Translational Research Center (MeTRC) PI, MMC-VICC-TSU Cancer Partnership NCI Grant Meharry Medical College John Murray, MD, PhD Key Experts Lucile L. Adams-Campbell, PhD Associate Director, Minority Health & Health Disparities Research Professor of Oncology, Lombardi Comprehensive Cancer Center Georgetown University Medical Center Rick A. Kittles, PhD Director, Division of Population Genetics Center for Applied Genetics and Genomic Medicine Professor, Cancer Biology, GIDP University of Arizona College of Medicine Professor, Department of Internal Medicine Associate Vice President for Research Meharry Medical College Isaac Powell, MD Professor, Department o fUrology Wayne State University Lucile L. Adams-Campbell, PhD Dr. Adams-Campbell is the Associate Director for Minority Health and Health Disparities Research, Associate Dean for Community Health & Outreach, and Professor of Oncology at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center. Dr. Adams-Campbell received her Ph.D. in Epidemiology from the Graduate School of Public Health at the University of Pittsburgh, becoming the first African-American female to receive a Ph.D. in epidemiology in the country. She has received numerous awards including the election to the Institute of Medicine in October 2008, Induction into the D.C. Hall of Fame, and is a graduate of the Executive Leadership in Academic Medicine (ELAM) program for women. She has received gold medallions awarded from both of her alma maters - University of Pittsburgh and Drexel University. She was appointed to the 2015 Dietary Guidelines Advisory Committee. Her areas of research focus on addressing health disparities with particular emphasis on cancers that disproportionately impact African Americans, primarily breast cancer. Dr. AdamsCampbell’s research expands to the areas of clinical trials, cancer epidemiology and etiology, and lifestyle interventions. Dr. Adams-Campbell has more than 185 publications. Rick A. Kittles, PhD Dr. Kittles helped establish the National Human Genome Center at Howard University. As co-director of molecular genetics, he directed large-scale, high thorough input genotyping and DNA sequencing projects. From 1997 to 2004, Kittles helped establish and coordinate a national cooperative network to study the genetics of hereditary prostate cancer in the African-American community. This project, called the AAHPC study network, successfully recruited over 100 multiplex African-American hereditary prostate cancer families and serves as a model for recruitment of African-Americans in genetic studies of complex diseases. Well known for his research of prostate cancer and health disparities among AfricanAmericans, Kittles has also been at the forefront of the development of ancestryinformative genetic markers, and how genetic ancestry can be used to map genes for common traits and disease. Currently, Dr. Kittles is Professor in the Division of Urology, Department of Surgery and Director of the Division for Population Genetics within the Center for Applied Genetics and Genomic Medicine, at the University of Arizona Health Sciences Center. Isaac Powell, MD Dr. Isaac Powell practices urologic oncology with an interest in prostate cancer. His grant funded research interests are in the genetics of prostate cancer development and the influence of race on cancer behavior, particularly in African-American men. Dr. Powell is a thought leader in prostate cancer and has published extensively on this disease process. Dr. Powell’s research focuses on the many ways prostate cancer impacts African Americans in comparison to other ethnic groups. Currently, his research is directed toward ethnic differences in the biology/genetics of prostate cancer. He was principle investigator of a nation-wide consortium of recruitment centers (medical centers) to recruit families to examine hereditary prostate cancer among African Americans. Powell was recently funded to examine Metabolic Syndrome and Prostate Cancer. He recently completed a study using the DASL technique and found that 60% of the prostate cancer genes that are differentially expressed and associated with advanced disease are different among AfricanAmerican compared to European-American men. Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee AGENDA FRIDAY, NOVEMBER 11, 2016 12:15 PM – 2:15 AM SCIENTIFIC NETWORKING SESSION & LUNCH Location: Ballroom This session is open to all trainees, faculty, and staff. It will include round table discussions with other conference participants, Key Expert Speakers, and Session Co-Chairs. This is an opportunity for discovering new collaborations, career development, and scientific brainstorming. ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... 17 ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. Poster Schedule Ballroom • 2nd Floor November 10. . . . . . . . . . 6:00 PM – 7:30 PM Join the discussion on social media using #MeharryTRC ABSTRACT LEGEND All posters are presented in the Ballroom Blue Ribbon Presentations – p. 19 1.0 HIV / AIDS – p. 23 2.0 Cancer – p. 23 3.0 Diabetes & Cardiovascular Disease – p. 25 4.0 Community & Population-Based Studies – p. 26 5.0 General, Dental, Medical, and Social Sciences – p. 27 Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. Blue Ribbon Presentations 1.10 TESTING OUR FAITH: HIV STIGMA AFTER A FAITH BASED A FAITH BASED HIV STIGMA REDUCTION INTERVENTION IN THE RURAL SOUTH P. Payne-Foster1, S. Gaskins2, E. Cooks1, B. Washington1, N. Adoloju-Ajijola3, J. Parton 4, X. Yang 4 1University of Alabama School of Medicine, Tuscaloosa campus, Institute for Rural Health Research, Tuscaloosa, United States, 2Capstone College of Nursing, Tuscaloosa, United States, 3University of Alabama, College of Human Environmental Sciences, Health Behavior, Tuscaloosa, United States, 4University of Alabama, Culverhouse College of Business Administration and Commerce, Department of Information Systems, Statistics, and Management Science, Division, Tuscaloosa, United States Recent literature suggests that HIV/AIDS related stigma may be an underlying cause of increasing HIV rates in Blacks in the Deep South. Black churches have a long-standing history of addressing community concerns, including health issues, but also have a history of HIV stigma. Effectively addressing racial/ethnic HIV disparities will require reductions in HIV-related stigma. We developed and pilot tested a faith-based anti-stigma intervention with 12 African-American churches in rural Alabama including two control arms. 196 participants were recruited and randomly assigned to three arms: Arm 1: Project FAITHH curriculum which emphasized anti-stigma, faith based messages; Arm 2: standard AIDS 101 curriculum; and Arm 3: HIV/AIDS educational pamphlets placed at the churches. Individual stigma (IS) was measured pre and post intervention using a 17 question parallel scale which measured total stigma as well as subsets of blaming (BJ) and interpersonal distancing (ID). Analyses included comparison IS, BJ and ID in all three arms and between arms using paired sample sign test and Mann Whitney U test. Analyses of pre/post-assessments showed individuals in Arm 1 reported a marginally significant reduction in BJ compared to the control group (p <.05). Our results also showed significant differences between pre and post-intervention ID (-0.57, p < 0.01) and IS (-1.00, p < 0.01) in Arm 2, though the differences of pre/post intervention between arms were not significant (Kruskal Wallis test). There were significant decreases in post-intervention ID (-0.45, p < 0.01) and IS (-0.71, p < 0.01 between Arms 2 and 3. Results from this pilot study support targeted faith-based anti-stigma messages as well as general HIV/AIDS 101 messages to decrease HIV/AIDS stigma. Findings also suggest that African-American churches may be poised to play a key role in efforts to reduce HIV stigma as an additional HIV prevention tool. GRANT SUPPORT: CDC, HIV/AIDS DIVISION, MINORITY AIDS RESEARCH INITIATIVE (MARI) FELLOWSHIP 2.04 ASSOCIATION OF CALCIUM SENSING RECEPTOR POLYMORPHISMS AT RS1801725 WITH CIRCULATING CALCIUM IN BREAST CANCER PATIENTS L Wang; SE Widatalla; DS Whalen; Josiah Ochieng; Ann Richmond; AM Sakwe Meharry Medical College (SEW, DSW, JO, AMS), Vanderbilt University (LW, AR) PURPOSE: Patients with metastatic or end-stage breast cancer (BC) inevitably develop hypercalcemia, while up to 30% of BC patients develop cancer-induced hypercalcemia (CIH) in the absence of metastases or bone diseases. The commonly diagnosed mild increase in circulating calcium activates the calcium sensing receptor (CaSR) and has been shown to be associated with larger and more aggressive breast tumors in postmenopausal and premenopausal patients respectively. Whether differences in circulating calcium and/or specific inactivating CaSR variants play any role in disparities in BC outcomes remains unclear. DESIGN METHODS: We identified 199 BC cases and 384 age and genetic ancestry-matched controls with calcium assay and genotyping data from the Vanderbilt University DNA biorepository (BioVU) linked to de-identified electronic medical records. The linear mixed effects and codominant models were used to assess the relationship between inactivating CaSR mutations at rs1801725 (codon 986) and rs1801726 (codon 1011) and either circulating calcium levels or risk of high calcium-driven aggressive BC outcomes. RESULTS: We observed that circulating calcium levels were significantly higher in BC cases compared to control subjects (p=0.001) and interestingly, in subjects of African ancestry compared to Caucasians (p=0.001). The A986S mutant CaSR is common among Caucasians while the Q1011E mutant receptor is common among African Americans. However, only inactivating mutations at rs1801725 locus were significantly associated with higher calcium levels (p=0.006) and a higher (69%) risk of high calcium-driven aggressive BC outcomes compared to the wild type receptor. We also demonstrate that invasive BC cells are tolerant to sustained high calcium and that their adaptation to high calcium occurs via up-regulation of calcium-activated early response and malignancy-associated genes. CONCLUSION: These data suggest that inactivating CaSR polymorphisms at rs1801725 predispose BC patients to hypercalcemia and that high circulating calcium-driven aggressive disease outcomes occur via calcium modulated malignancy-associated genes such as MAGEC2/CT10. GRANT SUPPORT: Supported by NIH/NIGMS 5SC2CA170244 (AMS); NIH/NIMHD 8U54MD007593 (Meharry Translational Research Center through a Pilot project to AS); 5U54CA163069 (Meharry/Vanderbilt/ Tennessee State Cancer Partnership). The datasets used for the analyses described her 2.08 BIOSYNTHESIZED MAGNETITE NANOPARTICLES: FROM ADHESION TO MRI FOR SPECIFIC TARGETING OF TRIPLE NEGATIVE BREAST CANCER J. D. Obayemi, J. Hu, V. O. Uzonwanne, K. Malatesta, and W. O. Soboyejo Mechanical and Aerospace Engineering, Princeton University In the search for specific targeting of breast cancer cells, one of the mechanism in the use of functionalized nanoparticles is driven by nanoparticles-cells interactions. Significant studies done on nanoparticlescell adhesion are yet to give insights at a nanoscale of ligands/antibody conjugated magnetite nanoparticles adhesion to cancer/normal breast cells. This paper presents the results of an experimental study of the adhesion forces between components of model conjugated magnetite nanoparticle systems/configurations for improved selectivity in the specific targeting of breast cancer. In this study, Atomic Force Microscope (AFM) was use to unravel and measure the adhesion interaction between biosynthesized magnetite nanoparticles (BMNPs)/conjugated BMNPs and breast cancer (MDA-MB-231) cells/normal breast (MCF 10A) cells. In each case, chemically synthesized magnetite nanoparticles (CMNPs) and conjugated CMNPs were used as a control. The BMNP constituents had adhesion forces (to breast cancer cells and normal breast cells) that were greater than that of CMNPs. The increased in adhesion interactions of BMNPs systems are attributed to Van der Waals interactions between conjugated nanoparticles and the overexpressed receptors (revealed by confocal images via immunofluorescence staining) on the surfaces of the breast cancer. In vivo studies also showed evidences of improve selectivity and specificity of conjugated BMNPs in detection of triple negative breast cancer via MRI imaging. The implication of the results suggest the potential use of BMNPs conjugates for rapid screening of potentials ligands/antibodies as well as the design of robust conjugated BMNPs as a contrast agent for enhancing magnetic resonance imaging (MRI) for specific targeting of triple negative breast cancer. GRANT SUPPORT: Princeton University Old School Funds 19 ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. 2.09 BORTEZOMIB IMPROVES ADOPTIVE CELL IMMUNOTHERAPY IN ADENOCARCINOMAS Samuel T. Pellom Jr., Menaka C. Thounaojam, Duafalia F. Dudimah, Ashutosh Singhal, Roman V. Uzhachenko, and Anil Shanker Meharry Medical College Tumor-induced immune suppression is a hallmark feature of tumor growth. Therefore, restoration of the antitumor immune response is a cornerstone of therapeutic interventions aimed to control tumor growth and improve the efficacy of immunotherapy. The therapeutic proteasome inhibitor bortezomib sensitizes solid tumors to apoptosis in response to TNF-family death ligands. We investigated the effects of bortezomib on lymphocyte responses and its potential to modulate the antitumor immune response in solid tumor mouse models. Bortezomib stabilized the expression of T-cell receptor CD3ζ and IL2 receptor-α, while maintaining IFNγ secretion to improve FasL-mediated tumor lysis. Notably, bortezomib increased tumor cell surface expression of Fas in mice as well as human melanoma tissue. We observed that bortezomib treatment also resulted in increased CD8+ T lymphocyte IFNγ secretion and expression of effector molecules, perforin and granzyme B, as well as the T-box transcription factor eomesodermin in tumor-bearing mice. Moreover, bortezomib promoted CD8+ T cell nuclear factor-κB (NFκB) activity by increasing the phosphorylated levels of the IκB kinase and IκBα as well as the cytoplasmic and nuclear levels of phosphorylated p65. We finally analyzed lymphoid and myeloid cells and their cytokine production profiles following bortezomib administration in tumor-bearing mice. Interestingly, Bzb treatment increased the levels of immunostimulatory interleukins IL-2, IL-12, IL-15. Further, in total splenocytes and myeloid cells, we found that bortezomib changed prosphorylation patterns of key signaling molecules in the JAK/STAT pathway, STAT3/5 in particular. Bortezomib administration also reduced tumor metastases to the lungs in 4T1-HA tumor-bearing mice. These findings provide novel insights on using bortezomib not only as an agent to sensitize tumors to cell death but also to enhance antitumor T cell function, provide lymphocyte-stimulatory effects, and help in modulating cytokine signaling, thereby overcoming immunosuppressive actions of tumor. GRANT SUPPORT: U54 CA163069 (NCI), U54 MD007593-04 (NIMHD), P50 CA 090949 (NCI), SC1 CA182843-01 (NCI/NIGMS), R01 CA175370 (NCI), RISE R25GM059994 (NIGMS), 5T32HL007737-18 (NHLBI) 2.18 GENDER AND DELIVERY METHOD TO IMPROVE BIOSPECIMEN DONATION IN BLACKS K Patel; J Gishe; F Pleban; C Brown; E Brown; C Jackson; MK Hargreaves Tennessee State University (KP, JG, FP, CB, EB); Meharry Medical College (CJ, MKH) PURPOSE: Human bio-specimens are an invaluable resource for addressing cancers and other chronic diseases. Molecular and genetic studies of bio-specimens contained in bio-banks may provide groundbreaking information about the etiology, diagnosis, and treatment of disease entities. The purpose of this study was to assess the impact of gender and delivery method on educational interventions for improving bio-specimen knowledge and attitudes among African Americans. DESIGN METHODS: Participants consisted of 112 African Americans, 18 years and older, who had not provided bio-specimens previously for cancer research. A total of 55 participants received the educational brochure and 57 received the educational video. Pre- and post-participant information was collected and reported. RESULTS: Average knowledge scores increased (p <.05) and average attitude scores for bio-specimen donation improved (p <.05) post intervention for both the video and brochure conditions. The delivery method had an impact on knowledge scores with the video method resulting in greater pre-post knowledge gain compared to the brochure method (p <.05). In addition, the gender of the participants also had an impact on knowledge scores with men having a greater knowledge gain pre-post compared to woman (p <.05). Delivery method and gender did not have an impact on attitudes towards bio-specimen donation. CONCLUSIONS: The results of this study demonstrated the feasibility and efficacy of using community-based participatory research strategies to develop educational tools for bio-specimen donation. In addition, delivery method and gender should be considered in developing educational interventions for bio-specimen donation. GRANT SUPPORT: The work is partially supported by U54 Ca 153708 2.35 ROLE OF TSPO IN AGRESSIVENESS OF TRIPLE NEGATIVE BREAST CANCER CELL LINES S Chakradhari, S Mukherjee, S Hari Gopal, SK Das Meharry Medical College We reported earlier that translocator protein (TSPO) is a biomarker for breast cancer. It is known that its expression is higher in estrogen receptor (ER)-negative than ER-positive breast cancer cells. Several reports indicate that African American (AA) women have higher grade breast tumors, higher incidence of triple negative breast cancers (TNBCs), higher proliferation indices, and node-positive disease than their Caucasian (C) counterparts. Among breast cancer patients, the mortality rate is higher in AA than C women. Our hypothesis is that the expression of TSPO is higher in TNBC than non-TNBC and that higher mortality rate among breast cancer in AA women is mechanistically linked to higher incidence of TNBC cells. To test this, we studied four TNBC (AA: HCC-1806 and MDA-MB-468; C: BT-549 and MDA-MB-231) and four non-TNBC (C: MCF-12A, MCF-12F, MCF-7, ZR-75-1) human cell lines obtained from ATCC for TSPO expression. The cultured cells were analyzed for protein by Western blot and gene expression by RT-PCR. Both protein levels and gene expression were significantly higher in TNBC cells than non-TNBC cells. There was no significant difference in either protein or gene expression of TNBC cells between AA and C. Our next plan is to confirm the above findings by immunohistochemistry as well as to include additional cell lines of both AA and C origin. For comparing functionality of TSPO between TNBC and non-TNBC cell lines, our future plan is to study cell proliferation, cell cycle progression, nuclear cholesterol transport and NTPase activity. Furthermore, we have initiated plan to obtain breast tumor samples of both TNBC and nonTNBC phenotypes for studying TSPO protein and gene expression. (The project was supported by MeTRC NIH grant: 5U54MD007593 GRANT SUPPORT: MeTRC grant 5U54MD007593 Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. 3.02 A PILOT STUDY FOR THE ELUCIDATION OF RELATIONSHIP BETWEEN HEMOGLOBIN A1C, INFLAMMATION AND CARDIOVASCULAR RISK STRATIFICATION IN PRE-DIABETIC INDIVIDUALS M SHOKRANI; J Phan; J Lukaszuk; V Flores Northern Illinois University (NIU); DeKalb, Illinois Pre-diabetic is a stage that can often go unnoticed and eventually progress to diabetes. There are millions of people who are not aware they are pre-diabetic. In particular, pre-diabetes affects disproportionately people of various ethnicities. While there are studies that link inflammation to the diabetic disorders, the link between inflammation, risk for cardiovascular events and pre-diabetic needs to be elucidated. Blood hemoglobin A1c (HbA1c) levels determine whether someone is pre-diabetic. The hsCRP (highly sensitive C-reactive protein) levels in the blood relate to inflammation cardiovascular risk stratification. In this pilot study, the levels of hsCRP, and anthropometric measurements such as body mass index (BMI) and percent body fat (PBF) of study participants were determined. Statistical analysis was used to determine the relationships among HbA1c, hsCRP, BMI, and PBF levels. The data in this pilot study suggest that high levels of HbA1c are related to a greater risk for inflammation and cardiovascular events. Future studies will define further these findings. GRANT SUPPORT: NIU USOAR; Also, Please note that I am a Meharry PhD Graduate in academia and strongly interested in studies related to diabetes in African Americans, Hispanics and Asian Americans.. 3.13 POOR SLEEP QUALITY IS ASSOCIATED WITH ADVERSE PREGNANCY OUTCOMES S Chirwa, CR Nwabuisi; GM Ladson; L Dakaud; R Atkinson; JE Whitty; JT Clark Meharry Medical College PURPOSE: Poor sleep quality is linked to metabolic dysregulation. Here, we tested the hypothesis that poor sleep quality is a risk factor for gestational diabetes (GD). METHODS: We recruited 38 pregnant women (16 nulliparous, 22 multiparous) and 21 non-pregnant women (age, 18-35 years; BMI 20-35). Sleep quality was assessed during gestational weeks 24-26 using the Pittsburgh Sleep Quality Index (PSQI) and Actigraphic watch. We also assessed depression, using a validated scale (CESDR). GD, blood glucose and cortisol levels were assessed. Three nulliparous and 5 multiparous participants were lost to follow-up and excluded from analysis. RESULTS: PSQI scores revealed a high incidence of poor sleep quality in pregnant women (73%) than non-pregnant women (43%). Actigraphic data showed no differences, in actual sleep hours between pregnant women (good sleepers, 7.53±0.54, n=8; bad sleepers, 7.20±0.19, n=21) and non-pregnant women (good sleepers, 7.26±0.28, n=12; poor sleepers, 7.51±0.32; n=9). However, there were more wake episodes (p=0.002), in pregnant mothers (episodes: 14±1) than in non-pregnant women (episodes: 9±1). Sleep fragmentation index (FR) was significantly higher (p=0.0009), in pregnant women (FR: 3.34±0.27) than in non-pregnant women (FR: 2.10±0.14). Clinical level depression was present in pregnant poor sleepers (CESDR scores: 16.4±3.80), but not in pregnant good sleepers (CESDR scores: 3.78±1.12), nor in non-pregnant women regardless of their sleep quality. Three pregnant mothers with poor sleep quality screened positive for GD at the 1-hour interval (blood glucose >153 mg/dL). Two women with poor sleep delivered babies with ponderal index >3.0, indicating macrosomia. There were no differences in average daily glucose levels between pregnant and non-pregnant women. However, morning cortisol levels were significantly increased (p=0.0003), in pregnant women (20.01±0.97 µg/dL) compared to non-pregnant women (13.58±1.39 µg/dL). Interestingly, higher cortisol levels were significantly correlated with good quality sleep in pregnant women (r= –0.5553±0.2110, n=27, p=0.0149). CONCLUSION: Our findings support our hypothesis. GRANT SUPPORT: NIH grant U54 RR026140 4.31 WEIGHT MANAGEMENT AND CARDIOMETABOLIC RISK REDUCTION: FAITH BASED PILOT INTERVENTIONS AMONG AT RISK AFRICAN AMERICANS IN NASHVILLE YE Zhou; C Jackson; VJ Oates; GW Davis; C Davis; Z Takizala; RA Akatue; K Williams; J Liu; JR Hebert; MS Buchowski; DG Schlundt; MK Hargreaves Meharry Medical College (YEZ, CJ, ZT, RAA, KW, JL, MKH), Tennessee State University (VJO, GWD, CD), University of South Carolina (JRH), Vanderbilt University (MSB, DGS) Objectives: The intervention aimed to test the effectiveness of a faith based weight control and cardiometabolic risk reduction program among high-risk middle-aged and older African Americans. Methods: The intervention was implemented twice at an African American Church, and consisted of two-hour weekly education sessions for 12 weeks, followed by monthly education sessions for three months. Results: Thirty four participants (aged 56.111 yrs, BMI 36.76.6) completed the intervention, with 11 of them participating twice whose 2nd round data were analyzed separately. Focus groups were conducted prior to both programs. After the 12 weekly sessions, the percentage of calories from fat decreased (from 40.31.6 % to 37.31.6 %, P=0.079) and sodium intake was reduced. Armband recorded sedentary activity time was reduced (from 210.4 to 19.40.4, h/day, P=0.0006). Body fat% among male participants decreased significantly (from 33.82.6 to 282.6, %, P=0.043). Among cardiometabolic risks, HbA1c decreased significantly (from 6.60.2 to 6.10.2, %, P=0.012). The baseline stress score was inversely associated with age (spearman r = -0.44, p=0.0084). Age in turn was inversely associated with baseline adiposity levels (weight, spearman r = -0.48, p=0.004) and was positively associated with the magnitude of weight loss (spearman r = 0.32, p=0.074) during the intervention. For the 11 individuals participating in the intervention twice, their HbA1c decreased more during the 1st round, whereas their LDL-cholesterol reduced more during the 2nd round, while their adiposity changes were not significantly different during the two rounds. After a three-month follow-up period, these improvements in weight control and cardiometabolic risks did not persist. Conclusion: The current study applied a more personalized approach to weight control and cardiometabolic risk reduction intervention. Future research is warranted on identifying successful strategies for early identification of risk factors and supportive behavioral models for maintenance of change among those individuals already impacted by chronic diseases. GRANT SUPPORT: This research was supported by funding from NIDDK grant 1 P30 DK092986 from the National Institute of Diabetes and Digestive and Kidney Diseases, and CNPC grant 3 U54 CA1 S3708-03 and GMAP grant 3U54CA153708-02S2 and 3U54CA153708-03S2 from the National Ca 21 ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. 5.02 TRAINING IN PATIENT-CENTERED COMPARATIVE EFFECTIVENESS RESEARCH: CHALLENGES AND SOLUTIONS D Landsittel, T Sentell, D Taira, J Southerland, MH Mays, M Henriques-Forsythe, K Kropf, M Norman Institute for Clinical Research Education, Department of Medicine, University of Pittsburgh, Pittsburgh, PA (DL, KK and MN); Office of Public Health Studies, University of Hawaii at Manoa, Honolulu, HI (TS); Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, Hawaii (DAT); Meharry Medical College, School of Dentistry, Nashville, TN (JS); Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus (MHM); Morehouse School of Medicine, Atlanta, GA (MH-F) Introduction: Translational research extends across a range of topics, from basic science to clinical research. At later phases of that spectrum, comparative effectiveness research (CER) seeks to evaluate direct comparisons of harms and benefits in real world settings, at the population and subgroup levels. More recently, the Patient-Centered Outcomes Research Institute (PCORI) was established by the Affordable Care Act to conduct CER which also answers questions about individual prognosis, options for treatment, and associated harms and benefits, and ways the patient and the care delivery systems can help improve outcomes. To advance these efforts, PCORI has funded over $1.5 billion in research. One of the greatest challenges in successfully conducting patient-centered CER, however, is training a sufficient number of researchers in the often complex methodologies and study designs. Methods: As part of the effort to address this critical need, the Agency for Healthcare Research funded five programs in PCOR training for specific research communities. One of those programs was the Expanding National Capacity in PCOR through Training, or ENACT Program. ENACT, which is partnership between six institutions (Charles R. Drew University, Howard University, Meharry Medical College, Morehouse School of Medicine, the University of Hawaii, the University of Pittsburgh, and the University of Puerto Rico), sought to develop expertise and infrastructure in PCOR at Minority-Serving Institutions. Results and Discussion: ENACT has developed two online courses that seek to train participants in developing a project concept, and a full proposal for funding; ENACT also includes a year-long experiential training component. A number of challenges have arisen, including the need to 1) more significantly focus training on writing funding proposals, 2) develop more easily accessible online approaches, and 3) initiate efforts to build long-term infrastructure. This talk will summarize the associated approaches to overcoming these and other challenges. GRANT SUPPORT: This research was supported by the Expanding National Capacity in Patient Centered Outcomes Research Through Training (ENACT) Program (grant number R25HS023185 from the Agency for Healthcare Research and Quality (AHRQ)) and also from the following Nationa Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. 1.0 – HIV / AIDS 1.01 CELLULAR EXONUCLEASE TREX1 INHIBITS HIV-1 INTEGRATION Benem-Orom Davids, Muthukumar Balasubramaniam, Jui Pandhare, and Chandravanu Dash Center for AIDS Health Disparities Research, Tennessee Center for AIDS Research (TN-CFAR), Department of Biochemistry and Cancer Biology, Department of Graduate Studies Research Meharry Medical College 1.02 COCAINE-INDUCED PROLIDASE ACTIVITY BREACHES THE BLOOD BRAIN BARRIER B BAHT YSRAYL; J Pandhare; C Dash Meharry Medical College (BbY; JP; CD) 1.04 HIV-1 CAPSID PROTEIN MODULATES THE ACTIVITY OF PREINTEGRATION COMPLEXES Muthukumar Balasubramaniam1, Amma Addai1, Jing Zhou2, Jui Pandhare1, Christopher Aiken2, and Chandravanu Dash1 1Center for AIDS Health Disparities Research, Meharry Medical College, Nashville, TN. 2Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 1.05 KAGERA MODEL: OPTIMIZING COMMUNITY AND FACILITY LINKAGES TO ENSURE RETENTION OF HIV/ AIDS PATIENTS IN CARE IN RESOURCE LIMITED SETTING. KI Pathan; MK Visram Emory University (KIP), Kagera Regional Health Department (KIP, MKV) 1.06 LATINX CONDOM SENSE IN LONG BEACH: PREVENTING HIV/ AIDS TRANSMISSION SALVADOR M. RAMIREZ, M Bird, PhD; M Garcia, MPH; D Aguirre, MPH; LA Cendejas, MPH California State University, Long Beach (SMR); Center for Latino Community Health, Evaluation, & Leadership Training (MB, MG, DA, LAC) 1.07 PREDICTORS OF BEING LOST TO HIV CARE AMONG PREGNANT AND POSTPARTUM WOMEN: A SYSTEMATIC REVIEW OJUKWU, EN; GONZALEZ-GUARDA, RM UNIVERSITY OF MIAMI SCHOOL OF NURSING AND HEALTH STUDIES (OEN, GGRM) 1.08 PROGESTERONE ENHANCES FEMALE HIV-1 TRANSMISSION THROUGH DECREASING LYSOSOMAL ACTIVITIES Xiangxu Jia, Qiujia Shao, Ballington Kinlock, Bobby Jones, Bindong Liu Meharry Medical College 1.09 2.03 RESULTS OF A PILOT STUDY ON HIV RISK AMONG AFRICAN AMERICAN DAUGHTERS WITH HIV+ MOTHERS NEUROTRANSMITTER GLUTAMATE RECEPTOR SIGNALING AFFECTS T CELL ACTIVATION Ndidi Amutah Montclair State University MTP de Aquino, T Hodo, A Shanker Meharry Medical College (MMC) 1.11 2.05 THE EFFECT OF METHAMPHETAMINE ON HIV-1-INDUCED NEUROCOGNITIVE DISORDERS VIA PROLINE OXIDASE BIOINFORMATICS ANALYSIS OF THE HOXA1 GENE REGULATORY NETWORK IN CANCER Bobby Jones; Sabyasachi Dash; Muthukumar Balasubramaniam; C.V. Dash and Jui Pandhare Center for AIDS Health Disparities Research (BJ,SD,MB,CD,JP), School of Graduate Studies and Research (BJ, CD, JP), Department of Microbiology and Immunology(BJ, JP) AA Smith Smith; E Martinez-Ceballos Southern University and A&M College (AAS, EMC) 1.12 A Roche-Lima; K Carrasquillo-Carrion; P Vivas; D VelazquezMorales; J Apiz CCRHD, University of Puerto Rico - Medical Science Campus (ARL, KCC, DVM), Biochemistry Dep., School of Medicine, University of Puerto Rico - Medical Science Campus THE ROLE OF FILAMIN A IN THE INTERACTION OF HIV-1 VPU AND BST-2/TETHERIN Dominique R. Dotson and Xinhong Dong Department of Microbiology and Immunology, Meharry Medical College, Nashville, TN 1.13 VIRAL LOAD SUPPRESSION AMONG HIV-INFECTED ADULTS IN MISSISSIPPI: ARE THERE DISPARITIES? A Firouzabadi Jackson state university 1.14 EXAMINING THE EFFECTS OF CHROMATIN STRUCTURE ON HIV-1 DNA INTEGRATION Nicklas E. Sapp 1,2, Muthukumar Balasubramaniam 1,2, Jui Pandhare 1,3, and Chandravanu (CV) Dash 1,2 1 Center for AIDS Health Disparities Research, 2 Department of Biochemistry and Cancer Biology, 3School of Graduate Studies and Research Meharry Medical College, Nashville, Tennessee, USA 2.0 – Cancer 2.01 “BUG YOUR DOC - GET 3 SHOTS!”: INTERVENTION TO INCREASE HPV VACCINATION PC HULL; EA Williams; JR Canedo; CR McAfee; D Khabele; M Sanderson Vanderbilt University Medical Center (PCH, CRM, DK); Tennessee State University (EAW); Meharry Medical College (JRC, MS) 2.02 A NOVEL MECHANISM ON EZH2 UBIQUITINATION AND TARGETING IN PROSTATE CANCER Wenfu Lu, Shenji Liu, Bo Li, Yingqiu Xie, Michael G. Izban, Billy R. Ballard, Sandeep Anantha Sathyanarayana, Samuel E. Adunyah, Robert J. Matusik and Zhenbang Chen Meharry Medical College, Nashville, TN, USA; Vanderbilt University Medical Center, Nashville, TN, USA 2.06 BIOINFORMATICS TOOLS TO ASSOCIATE MIRNAS TO CANCER FOCUSED ON HISPANICS 2.10 CHILDHOOD ACUTE MYELOID LEUKEMIA TRENDS: SEX OR RACIAL VARIANCE? L Brenes, M Gray, K Dabney, L Holmes Nemours/AIDCH Office of Health Equity & Inclusion, USA (LB, MG, KD, LH), James Madison University, USA (MG), University of Delaware, USA (LH) 2.11 DELAWARE PEDIATRIC CANCER SURVIVAL: RACIAL AND SEX DISPARITIES? L BRENES, L Nguyen, K Dabney, L Holmes Nemours/AIDCH Office of Health Equity & Inclusion, USA (LB, LN, KD, LH), Villanova University, USA (LN), University of Delaware, USA (LH) 2.12 DEPENDENCE ON GLYCOLYSIS SENSITIZES BRAF-MUTATED MELANOMAS FOR INCREASED RESPONSE TO TARGETED BRAF INHIBITORS KN Hardeman, C Peng, BB Paudel, CT Meyer, T Luong, DR Tyson, JD Young, V Quaranta, and JP Fessel Vanderbilt University Medical Center (KNH, CP, BBP, CTM, TL, DRT, VQ, & JPF), Vanderbilt University (JDY) 2.13 DESIGN AND SYNTHESIS OF 7-ALKYL DERIVATIVES OF TESTOSTERONE FOR STUDY IN PROSTATE CANCER CELL LINES C Mouamba; V Talanov; O Bakare Howard University 2.15 DIBUTYLTIN ALTERS INTERLEUKIN 1 BETA AND INTERLEUKIN 6 SECRETION FROM HUMAN IMMUNE CELLS Brown, Shyretha, Shahin Tehrani, Wendy Wilburn, and Margaret M. Whalen Department of Biological Sciences, Department of Chemistry, Tennessee State University, 3500 John A. Merritt Blvd., Nashville, TN 37209 23 ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. 2.16 2.25 2.32 DOES ESTROGEN PROVIDE PROTECTION AGAINST BENZO(A) PYRENE [B(A)P]-INDUCED COLON CARCINOGENESIS? INVOLVEMENT OF PROINFLAMMATORY CHEMOKINES IN TRIPLE NEGATIVE BREAST CANCER (TNBC) PANOBINOSTAT SENSITIZES CYCLIN E HIGH, HOMOLOGOUS RECOMBINATION-PROFICIENT OVARIAN CANCER TO OLAPARIB Kenneth J. Harris, Kelly L. Harris, Anthony Archibong, Mary K. Washington, and Aramandla Ramesh Meharry Medical College (KJH, KLH, AA, AR), Vanderbilt University (MKW) Rosa Mistica C. Ignacio, Carla R. Gibbs, Eun-Sok Lee, Deok-Soo Son Meharry Medical College Wilson, A.J ., Sarfo-Kantanka, K ., Steck, A ., Saskowski, J ., Crispens, M ., Khabele, D Department of Obstetrics & Gynecology, Division of Gynecologic Oncology - Vanderbilt University Medical Center (WAJ, SA, SJ, CM, KD), Meharry Medical College (KSK) 2.17 FETUIN-A AND GALECTIN-3 AUTOANTIBODIES AS SURROGATE BIOMARKERS OF EARLY DETECTION IN BREAST AND PROSTATE CANCER PATIENTS. Gladys Nangami, Ph.D., Ebenezar Appah, M.D. , Samaria Hargraves, B.S.,Michael G. Izban, Ph.D., Billy R Ballard M.D., D.D.S., Philip E. Lammers, M.D., MSC., and Josiah Ochieng, Ph.D. Mehhar Medical College 2.20 HPV VACCINE INITIATION AND COMPLETION FOLLOWING A PROVIDER INTERVENTION DELIVERED AT COMMUNITY HEALTH CENTERS M Sanderson, J Canedo, D Khabele, MK Fadden, M Hargreaves, C Jackson, P C. Hull Meharry Medical College (MS, JC, MKF, MH, CJ), Vanderbilt University (DK, PCH) 2.21 HYPERGLYCEMIA, DIABETES, GLUCOSE INTOLERANCE, AND CARCINOGENESIS 2.26 LACTATE DEHYDROGENASE EXPRESSION IN AFRICAN AMERICAN WOMEN WITH TRIPLE-NEGATIVE BREAST CANCER O Torres-Luquis; J Thystrup; S Mohammed Purdue Univeristy 2.33 2.27 Roman V Uzhachenko#; Ashutosh Singhal#; Shawn J. Goodwin#; Lino Costa$; Alexander Terekhov$; Menaka C Thounaojam#; William H Hofmeister$; and Anil Shanker#* Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN; $Center for Laser Applications, University of Tennessee Space Institute, Tullahoma, TN; *Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN MEASURING IMPLEMENTATION OF AN EVIDENCE-BASED PALLIATIVE CARE MODEL GA MANCARELLA; JN Dionne-Odom; L Zubkoff; D Babu; I Akyar; TR Smith; M Pisu; MA Bakitas School of Nursing, University of Alabama at Birmingham, Birmingham, AL (GAM, JND, IA, TRS, MAB); White River Junction VA Medical Center, White River Junction, VT (LZ); Department of Medicine, University of Alabama at Birmingham, Birmingham, AL (DB, MP) 2.28 O Obanor; E Olokpa; S Mandape; S Pratap; LV Stewart Meharry Medical College (OO, EO, SM, SP, LVS) 2.37 2.22 2.23 IMPLICATION OF NEIGHBORHOOD DISADVANTAGE IN THE INCIDENCE OF COLORECTAL CANCER IN LOUISIANA DM DANOS; TF Ferguson; NR Simonsen; C Leonardi; Q Yu; X Wu; RA Scribner Louisiana State University Health – New Orleans, School of Public Health and Louisiana Cancer Research Center (DMD, TFF, NRS, CL, QY, RAS), Louisiana Tumor Registry (XW) 2.24 RU486 REGULATES PROLIFERATION AND PPARΓ EXPRESSION IN HUMAN PROSTATE CANCER CELL LINES Tonie Farris; LaMonica Stewart PhD Tennessee State University 2.29 R Selove; C Green; C Brown; N Yousef-Zadeh; D Padgett All at Tennessee State University (TSU) 2.36 METFORMIN REGULATES MANY SIGNALING PATHWAYS IN PROSTATE CANCERS L Holmes, Jr.; L Nguyen; MA Gray; AJ Filippini; K Dabney; LA Stalnaker Nemours/Alfred I. duPont Hospital for Children (LH, LN, MAG, AJF, KD, LAS), University of Delaware (LH), Villanova University (LN), James Madison University (MAG), West Chester University (AJF), Liberty University (LAS) IMPLEMENTING TOBACCO USE PREVENTION PROGRAMS AT AN HBCU PHYSICAL INTIMACY BETWEEN CD8+T AND NATURAL KILLER CELLS ELICITS EFFECTOR RESPONSE MIR-130A MEDIATED REGULATION OF THE GROWTH REGULATOR PROTEIN ZAR2 IN BREAST CANCER CELLS SIGNALING PATHWAYS INVOLVED IN TRIBUTYLTININDUCED INCREASES IN INTERLEUKIN 6 PRODUCTION BY LYMPHOCYTES Smita Misra; Gautam Chaudhuri Meharry Medical College Nafisa Hamza, Shyretha Brown, and Margaret Whalen Departments of Biological Sciences and Chemistry, Tennessee State University 2.30 2.38 A RARE CASE OF PRIMARY INVASIVE PAPILLARY ADENOCARCINOMA OF VULVAR LESION SNAIL TRANSCRIPTION FACTOR REGULATES NUCLEAR CATHEPSIN L ACTIVITY Robinette H. King Morehouse School of Medicine Liza J Burton1 Camille Ragin2, and Valerie Odero-Marah1 1Center for Cancer Research and Therapeutic Development, Department of Biological Sciences, Clark Atlanta University, Atlanta, GA 30314; 2Fox Chase Cancer Center-Temple Health, Philadelphia, PA 19111 2.31 NOTCH RECEPTOR-LIGAND INTERACTION DURING CD8+ T CELL – NK CELL CROSSTALK PL Thomas; A Shanker Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN; Department of Microbiology and Immunology, School of Medicine, Meharry Medical College, Nashville, TN; School of Graduate Studies and Research, Meharry Medical College, Nashville, TN; Host-Tumor Interactions Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 2.39 TETRASPANIN GENE EXPRESSION IN ORAL SQUAMOUS CELL CARCINOMA TISSUE BC MACCHIARELLA; YH Zhang; Q Zheng; MK Anderson; F GarciaGodoy College of Dentistry, University of Tennessee Health Science Center at Memphis (YHZ, QZ, MKA, FGG) ; Meharry Medical College, School of Dentistry (BCM) INCREASED EXPRESSION OF LONG-NONCODING RNA ZFAS1 IN GASTRIC CANCER AND ITS SIGNIFICANCE Ke Wu; Yong Wu;Fubing Wang Charles Drew University of Medicine and Science(Ke Wu,Yong Wu),Zhongnan Hospital of Wuhan University(Fubing Wang) Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. 2.40 3.05 3.16 THE NATURAL COMPOUND DERIVATIVE INHIBITS GROWTH OF BREAST CANCER CELLS UNDER DIABETIC CONDITIONS DIABETES HEALTH-SEEKING BEHAVIORS AMONG AFRICAN AMERICAN WOMEN Mohammad Atefi, Lynn Ma, Ke Wu, Seyung Chung, Qiao-Hong Chen, Guangdi Wang, Yong Wu and Jay Vadgama Division of Cancer Research and Training, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA. David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA. RCMI Cancer Research Center, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA 70125, USA; Department of Chemistry, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA 70125, USA. Department of Chemistry, California State University, Fresno, 2555 E. San Ramon Avenue, M/S SB70, Fresno, CA 93740, USA. ST Miller; SA Akohoue Meharry Medical College (STM, SAA) SALIVARY PROTEOMICS PROVIDING THE INTERFACE AMONG CARDIOVASCULAR DISEASE AND STRESS IN FEMALE AFRICAN AMERICAN IPV EXPOSED VICTIMS 2.41 3.07 THE ROLE OF ESTROGEN RECEPTOR BETA (ER) AND INSULIN GROWTH FACTOR 2 (IGF2) IN TRIPLE-NEGATIVE BREAST CANCER David Austin, Nalo Hamilton, Yahya Elshimali, Richard Pietras, Yanyuan Wu, Jay Vadgama Division of Cancer Research Charles Drew University (DA, YE, YW, JV) UCLA- Jonsson Comprehensive Cancer Center and School of Nursing (NH), Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles (RP) 3.06 DIFFERENCES IN THE NEUTROPHIL-LYMPHOCYTE RATIO ACROSS RACIAL/ETHNIC GROUPS DN GUILLORY; ST Broyles; SM Thomas Behavioral and Community Health Sciences, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana (DNG, SMT); Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana (STB) Durham, J, Shealer M, Cho R, Rogers J, Padron V, Isaza S, Southerland J,Gangula,P, Tabatabai M, Young ,D, Halpern LR Departments of Oral Biology & Oral and Maxillofacial Surgery, School of Dentistry , Department of Masters in Public Health, School of Graduate School & Research 3.17 SEX DIFFERENCES IN HEALTHCARE EXPENDITURES AMONG ADULTS WITH DIABETES JS Williams; KG Bishu; CE Dismuke; LE Egede Medical University of South Carolina (JSW, KGB, CED) & Ralph H. Johnson VAMC (CED, LEE) EAST COAST DIVIDE: RESULTS OF THE ENABLE CHF-PC EARLY, CONCURRENT PALLIATIVE CARE HEART FAILURE PILOT CLINICAL TRIAL 3.18 RD WELLS, JN DIONNE-ODOM, D EJEM, E KVALE, M BAKITAS School of Nursing, University of Alabama at Birmingham, Birmingham, AL (RDW, JNDO, DE, MB); Department of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, AL (EK, MB) JS Williams; KG Bishu; A St. Germain; LE Egede Medical University of South Carolina (JSW, KGB, AS, LEE) & Ralph H. Johnson VAMC (LEE) 3.08 ESTIMATING THE INCIDENCE OF DIABETES IN A COHORT OF VETERANS DIAGNOSED WITH TRAUMATIC BRAIN INJURY SEX DISPARITY IN QUALITY OF CARE INDICATORS AMONG ADULTS WITH DIABETES 3.19 TRYPANOSOMA CRUZI REGULATES FIBROGENIC GENES IN PRIMARY HEART CELLS 3.0 – Diabetes & Cardiovascular Disease RJ Walker; CE Dismuke; B Wojciechowski; LE Egede Medical University of South Carolina (RJW, CED, LEE), Ralph H. Johnson VAMC (RJW, CED, BW, LEE) PN Nde; AN Udoko; CA Johnson; D Andrey; G Rachakonda; F Villalta; S Mandape; MF Lima and S Pratap Meharry Medical College (PNN, DA, GR, FV, SM, MFL and SP); The University of Tennessee Health Science Center (ANU); Food and Drug Administration (CAJ) 3.01 3.09 3.20 EXPLORING RACIAL DISPARITY IN OBESITY: A MEDIATION ANALYSIS UPREGULATION OF CHOLESTEROL ABSORPTION BY CHOLECYSTOKININ IN HUMAN INTESTINAL EPITHELIAL CELLS Q Yu; C Leonard; NR Simonseni; C Park; L Chen; RA Scribner School of Public Health, Louisiana State University Health Sciences Center; Department of Public Health Sciences, Clemson University N Zhang; L Dent; H Yang; EU Okoro; ZM Guo Meharry Medical College 3.11 VALIDITY AND RELIABILITY OF A SELF-REPORTED MEASURE OF DIET IN PATIENTS WITH DIABETES A CORRELATION AMONG EXPOSURE TO INTIMATE PARTNER VIOLENCE (IPV), SALIVARY BIOSENSORS AND RISK FOR CARDIOVASCULAR DISEASE (CVD) E McMichael; M Shealer; R Cho; J Rogers; V Padron; S Isaza; D Young; J Southerland; C Farmer-Dixon; M Tabatabai; P Gangula; L Halpern Departments of Oral Biology & Oral and Maxillofacial Surgery, School of Dentistry, Department of Master of Science in Public Health, School of Graduate Studies & Research, Meharry Medical College, and Nashville, TN 3.03 AKT ISOFORM-DEPENDENT REGULATION OF ATP-BINDING CASSETTE A1 EXPRESSION BY APOLIPOPROTEIN E. EU Okoro; ZM Guo; H Yang Meharry Medical College 3.04 CHARACTERIZATION OF INNATE IMMUNE RESPONSES OF HUMAN ENDOTHELIAL CELLS INDUCED BY PORPHYROMONAS GINGIVALIS AND THEIR DERIVED OUTER MEMBRANE VESICLES MH Ho, Z Guo, J Chunga, JS Goodwin, and H Xie Meharry Medical College MODELING OPHTHALMOLOGIC DATA STRUCTURES: APPLICATION TO ANALYSES OF DIABETIC RETINOPATHY 3.21 John Kwagyan, PhD Howard Univerity College of Medicine SA AKOHOUE; KA Wallston; DG Schlundt; RL Rothman Meharry Mdical College (SAA), Vanderdilt University (KAW, DGS), Vanderbilt Center for Health Services Research (RLR) 3.14 3.22 RACIAL DIFFERENCES IN OUT OF POCKET COSTS AND TOTAL EXPENDITURES IN PATIENTS WITH TYPE 2 DIABETES VASCULAR PROTEASOMAL DEGRADATION OF MLCK DURING HYPOXIA Aprill Z Dawson, MPH, Rebekah J Walker, PhD, Kinfe G Bishu, PhD, Leonard E Egede MD, MS Medical University of South Carolina, Ralph H Johnson VA Medical Center OO Adeoye; D Sorensen; JM Williams; WJ Pearce Center for Perinatal Biology, Loma Linda University School of Medicine Loma Linda CA (DS, JMW, WJP) Pharmaceutical and Administrative Sciences, School of Pharmacy Loma Linda CA (OOA) 3.15 RACIAL DIFFERENCES IN SPATIAL PATTERNS FOR POOR GLYCEMIC CONTROL IN THE SOUTHEASTERN US RJ Walker, M Davis, B Neelon, LE Egede Medical University of South Carolina (RJW, MD, BN, LEE), Ralph H. Johnson VAMC (RJW, LEE) 25 ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. 3.23 4.05 4.13 RACIAL/ETHNIC DISPARITIES IN DIABETES QUALITY OF CARE: THE ROLE OF HEALTHCARE ACCESS AND SOCIOECONOMIC STATUS ASSOCIATION OF CONCENTRATED DISADVANTAGE WITH CANCER INCIDENCE IN LOUISIANA EXPLORING POTENTIAL DISPARITIES IN EARLY PRENATAL CARE IN MISSISSIPPI TF FERGUSON; DM Danos; NR Simonsen; C Leonardi; Q Yu; X Wu; RA Scribner Louisiana State University Health – New Orleans, School of Public Health and Louisiana Cancer Research Center (TFF, DMD, NRS, CL, QY, RAS), Louisiana Tumor Registry (XW) M Qobadi; L Zhang Mississippi State Department of Health (MQ, LZ) JR Canedo; S Miller-Hughes; D Schlundt; MK Fadden; M Sanderson Meharry Medical College (JRC, SM-H,MKF, MS ), Vanderbilt University (DS) 4.0 – Community & Population-Based Studies 4.01 ACCESS TO MEDICATIONS FOR MEDICARE ENROLLEES RELATED TO RACE/ETHNICITY: RESULTS FROM THE 2013 MEDICARE CURRENT BENEFICIARY SURVEY Deborah A. Taira, ScD;1 Chengli Shen, PhD; 2 Marshaleen Henriques-Forsythe, MD, MSCR, FCCP;3 Doug Landsittel, PhD;2 Mary Helen Mays;4 Tetine Sentell, PhD;5 Janet Southerland, DDS, MPH, PhD6 1Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, Hawaii; 2Section on Biomarkers and Prediction Modeling, Department of Medicine, University of Pittsburgh, Pittsburgh, PA; 3Morehouse School of Medicine, Atlanta, GA; 4Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus;; 5Office of Public Health Studies, University of Hawaii at Manoa, Honolulu, HI; 6Meharry Medical College, School of Dentistry, Nashville, TN 4.02 ANALYZING THE ROLE OF HIGH PRO-INFLAMMATORY DIETS AND CHILDHOOD OBESITY IN THE RISK OF ADULT CARCINOGENESIS IN SOUTH CAROLINIAN CHILDREN SG Brown; AE Knowell South Carolina State University 1890 Research (SGB and AEK) 4.03 ASSESSMENT OF HIV KNOWLEDGE AND FACTORS ASSOCIATED WITH IT AMONG PARTICIPANTS IN NORTH MIAMI-DADE COUNTY HOUSEHOLDS. A. I. Parrigan; S. J. Woolford, MD, MPH University of Michigan Health System (AIP); University of Michigan Child Health Evaluation and Research Unit (SJW) FROM SOCIAL CAPITAL TO COMMUNITY OUTCOMES: A SOCIAL NETWORK STUDY OF THE ABILITY TO FOSTER COLLABORATION FOR ADDRESSING HEALTH DISPARITIES AT THE COMMUNITY LEVEL CF BRIGHT; E EDMONSON, D PATTERSON THE UNIVERSITY OF SOUTHERN MISSISSIPPI (CFB), THE UNIVERSITY OF ALABAMA AT BIRMINGHAM (EE), BAYOU CLINIC, INC (DP) 4.07 4.15 4.06 BARRIERS TO FRUIT & VEGETABLE INTAKE IN AT-RISK POPULATIONS BLACK, WHITE, AND BLUE: PERCEPTIONS OF POLICE ON DEPRESSIVE SYMPTOMS BY RACE IN THE CHICAGO COMMUNITY ADULT HEALTH STUDY KM Brown, AJ Owuka Center for Epidemiology and Population Health- University of Michigan (KB, AO), Center for Research on Ethnicity, Culture, and Health-University of Michigan (KB, AO), Center for Integrative Approaches to Health Disparities-University of Michigan (KB, AO) 4.08 CALLING IT QUITS PL JACKSON MedStar Washington Hospital Center (PLJ) 4.09 COLORECTAL CANCER SCREENING AND EXERCISE AMONG OVERWEIGHT OLDER ASIAN AMERICANS: COMMUNITYBASED PARTICIPATORY RESEARCH SW Jin; J Lee Clark Atlanta University (SWJ), University of Minnesota (JL) 4.10 DESEO: DEPRESSION SCREENING AND EDUCATION: OPTIONS TO REDUCE BARRIERS TO TREATMENT CL Holder; V Nwudu;V Alvarez;P Bhoite Florida International University Katherine Sanchez University of Texas at Arlington 4.04 4.11 ASSOCIATION BETWEEN HAIR CORTISOL CONCENTRATIONS AND INCREASED STRESS LEVELS FOLLOWING INTERPERSONAL VIOLENCE: CHILDHOOD MALTREATMENT AS A MODERATOR MC Morris; AS Mielock; U Rao Meharry Medical College (MCM, ASM), Vanderbilt University (MCM, UR), University of Tennessee Knoxville (UR) 4.14 DETERMINING FEASIBILITY OF A SOCIAL MARKETING CAMPAIGN TO INCREASE FARMERS MARKET USE AMONG SNAP RECIPIENTS. H Nuss, M Skizm, M Sothern Louisiana State University Health Sciences Center School of Public Health 4.12 ENHANCED EMOTIONAL INTELLIGENCE WITH A HEALTH DISPARITY CURRICULUM MH Parks; C Haygood; CK Chen; ML McGee Meharry Medical College (MHP, CH, CKC, MLM); Community Leadership Institute for Health Equity (MHP, MLM) HEALTH DISPARITIES IN ADOLESCENT RISK ASSESSMENT A BAHAMONDE; RA Blackwood; YA Civil University of Michigan Department of Pediatrics and Communicable Diseases (AB, RAB, YAC) 4.16 HEALTH DISPARTIES AND COMORBIDITY AMONG OLDER AFRICAN AMERICAN MEN Gail Wallace Johns Hopkins University 4.17 HEALTH POLICY LITERACY: BRIDGING THE GAP BETWEEN COMMUNITY, SCIENCE, AND POLICY AS Hawkins; KD Sydnor; J Sankofa; B Sogie-Thomas Morgan State University School of Community Health and Policy (KDS, ASH); Health Policy Research Consortium (JS, BST). 4.18 PILOT PROTEOMIC STUDY OF INTIMATE PARTNER VIOLENCERELATED BIOMARKERS IN HUMAN SALIVA V. Paromov, S. Pratap, P. Gandula and L. Halpern Proteomics Core Facility, Meharry Clinical and Translational Research Center (MeTRC), School of Dentistry, Meharry Medical College, Nashville, Tennessee 4.19 POSTPARTUM CONTRACEPTIVE CHOICE AND ADHERENCE AT AN URBAN HOSPITAL CENTER Twyner, Maesha, M.D.,M.P.H., Saint Louis, Hedwidge, M.D.,M.P.H., F.A.C.O.G. Morehouse School of Medicine 4.20 RACE & SOCIAL DETERMINANTS IMPLICATIONS IN PEDIATRIC DENTAL DISORDERS LA Stalnaker; L Holmes, Jr.; AO Jones; K Dabney Nemours/Alfred I. duPont Hospital for Children (LAS, LH, AOJ, KD), Liberty University (LAS), Wesley College (AOJ), University of Delaware (LH) Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. 4.21 4.28 5.08 RACIAL/ETHNIC DIFFERENCES IN THOSE ACCOMPANYING MEDICARE PATIENTS TO THE DOCTOR: INSIGHTS FROM THE 2013 MEDICARE CURRENT BENEFICIARY’S SURVEY THE RELATIONSHIP BETWEEN MUSLIMS’ PERCEPTIONS OF ISLAMOPHOBIA AND PERCEIVED HEALTHCARE BARRIERS DIFFERENTIAL EFFECT OF PORPHYROMONAS GINGIVALIS LIPOPOLYSACCHARIDES ON MONOCYTIC CELLS TO SECRETE INFLAMMATORY CYTOKINES AND SLPI. T Sentell; C Shen; D Landsittel; MH Mays; J Southerland; M Henriques-Forsythe; DA Taira Office of Public Health Studies, University of Hawaii at Manoa, Honolulu, HI (TS); Section on Biomarkers and Prediction Modeling, Department of Medicine, University of Pittsburgh, Pittsburgh, PA (CS and DL); Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus (MHM); Meharry Medical College, School of Dentistry, Nashville, TN (JS); Morehouse School of Medicine, Atlanta, GA (MH-F); Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, Hawaii (DAT) 4.22 RACIAL/ETHNIC VARIANCE IN CHILDHOOD IMMUNIZATIONS LA Stalnaker; L Holmes Jr; AJ Filippini; K Dabney Nemours/Alfred I. duPont Hospital for Children (LAS, LH, AJF, KD), Liberty University (LAS), University of Delaware (LH), West Chester University (AJF) 4.23 REACHING RACIAL/ETHNIC MINORITY POPULATIONS SUFFERING FROM HEALTH DISPARITIES: PRELIMINARY OUTCOMES OF A NURSING STUDENT HEALTH FAIR PROGRAM SALERNO, J.P., MPH; Williams, J.R., PhD, MPH, APHN-BC; Azaiza, M., BSN(c); Hardy, D., BS(c) University of Miami School of Nursing & Health Studies – Center of Excellence for Health Disparities Research: El Centro (JPS, JRW, MA, DH) 4.24 REDUCING DISPARITIES IN QUITLINE UTILIZATION THROUGH GROUP DESENSITIZATION COUNSELING IN A RURAL PUBLIC HOSPITAL MD CELESTIN; SM Thomas; Q Yu; TS Tseng; D Durapau; K Wynn; DN Guillory Behavioral and Community Health Sciences, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana 4.26 SUBSTANCE ABUSE EXPOSURE & CHILDHOOD TRAUMATIC BRAIN INJURIES L Holmes, Jr.; LA Stalnaker; CF Elliott; K Dabney Nemours/Alfred I. duPont Hospital for Children (LH, LAS, CFE, KD), University of Delaware (LH), Liberty University (LAS), Rowan University (CFE) 4.27 THE COMPONENTS OF COMMUNITY-BASED ORGANIZATION ENGAGEMENT (CBOE): A SYSTEMATIC REVIEW OW Adebayo, JR Williams, JP Salerno, VL Francillon University of Miami AM Alshehri; JC Barner; CM Carolyn; KH Ford; KL Rascati; SA Atif College of Pharmacy at The University of Texas at Austin (AMA, JCB CMC KHF KLR); College of Pharmacy at Prince Sattam Bin Abdulaziz University (AMA); Muslim Children Education and Civic Center (SAA) 5.0 – General, Dental, Medical, and Social Sciences 5.01 150 YEARS LATER: FEDERAL AND STATE HEALTH EQUITY EFFORTS, 1865-2015 C.R. Trice; J.P. Babu Meharry Medical College (CRT); University of Tennessee Health Science Center (JPB) 5.09 DOPAMINE TRANSPORTER INTERACTOME WHEN EXPOSED TO PSYCHOSTIMULANTS Shalonda Ingram, Tanu Rana, Victor Paromov, Siddharth Pratap and J. Shawn Goodwin Meharry Medical College 5.10 EXPOSURE TO ACCULTURATIVE STRESS PREDICTS MORNING CORTISOL PROFILES LINKED TO HEALTH OUTCOMES IN MEXICAN AMERICANS S Thomas, J Sankofa, B Sogie-Thomas. Center for Health Equity, University of Maryland School of Public Health (ST); Health Policy Research Consortium (JS, BST). A. F. Garcia, M.A.; K. Wilborn, Ph.D.; D. L. Mangold, Ph.D. The University of Texas at San Antonio (AFG, DLM), The University of Houston (KW) 5.04 5.11 AUTOANTIBODIES ACTIVATE THE ALTERNATIVE PATHWAY OF COMPLEMENT IN KIDNEY DISEASE IMPAIRMENT OF BH4/NO/NRF2-PHASE II SIGNALING PATHWAY IN HUMAN COLITIS DB Borza, T Rana, LH Beck Meharry Medical College (DBB, TR), Boston University (LHB) PR Gangula, D Smoot, S Adunyah Meharry Medical College 5.05 5.12 BETA-ARRESTIN1 AND TESTOSTERONE IN PREMENSTRUAL DYSPHORIC DISORDER K SMITH; F Alam; A Archibong; T Nayyar Meharry Medical College, Nashville, TN 5.06 COCAINE-INDUCED DOWN-REGULATION OF MIR-125B MODULATES THE EXPRESSION OF POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1) Sabyasachi Dash1,2, Muthukumar Balasubramaniam1,4, Erin Calipari5, Tanu Rana4, J. Shawn Goodwin4, Fernando Villalta1,2,3, Eric Nestler5, Chandravanu Dash1,2,4 *, and Jui Pandhare1,2,3 * 1Center for AIDS Health Disparities Research, 2Department of Graduate Studies and Research, 3Department of Microbiology and Immunology, 4Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, Tennessee, 37208, USA And 5Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029; USA 5.07 CONNECTING THE DOTS: MEETING THE DIAGNOSTIC AND TREATMENT NEEDS OF UNDERSERVED URBAN AFRICAN AMERICAN ELDERS WITH MEMORY LOSS Gina Green-Harris; Teresa Skora; Stephanie Houston; Carla Wright;Dorothy Edwards University of WI-Madison, Milwaukee Health Services, Inc. POLYBACTERIAL INFECTION INHIBITS NITRIC OXIDE & ANTIOXIDANTS THROUGH MODULATION OF THE COLON MICROBIOME Miriam Y. Walker, Siddharth Pratap, Shruti S. Sakhare, Sammed Mandape, Janet H. Southerland, Cherae Farmer-Dixon , Kesavalu, L, Pandu Gangula Department of Oral Biology, Department of Biomedical Informatics, Department of Oral Surgery; School of Dentistry; Meharry Medical College, Nashville TN; School of Dentistry, University of Florida, Gainesville, FL 5.14 REDUCING PATHOGENS OF PUBLIC HEALTH CONCERN THROUGH APPLICATION OF ELEVATED HYDROSTATIC PRESSURE E. Daniels, S. Chowdhury, A FOULADKHAH* Public Health Microbiology Laboratory of Tennessee State University 5.16 SOCIOCULTURAL AND EMOTIONAL SUICIDE RISK ASSESSMENT COMPETENCIES Y Brown National Organization For People of Color Against Suicide 5.17 SYNTHESIS AND CHARACTERIZATION OF POLYCAPROLACTONE (PCL) MEMBRANES AS SCAFFOLDS FOR BONE TISSUE REGENERATION EA Dwomoh; J Santillàn; EO Ortiz-Quiles; E Nicolau City College Of New York 27 ABSTRACTS Abstracts and authors are listed as submitted and have not been edited. 5.18 THE EFFECT OF RACIAL ETHNICITY DISPARITIES IN SALIVARY FLOW RATE AMONG DENTAL PATIENTS AT MEHARRY MEDICAL COLLEGE, SCHOOL OF DENTISTRY E Alston, A. Borders, J McKinnis, R Graham, A Artis, R. Simeon, V Hopkins, R. Alexander, V McShan, P Gangula, J Southerland Meharry Medial College, School of Dentistry 5.19 THE SHRUB THAT KEEPS GIVING: VERNONIA AMYGDALINA; EFFECT ON HUMAN SEMEN CRYOSTORAGE Anthony E. Archibong Meharry Medical College 5.21 RESEARCHMATCH: AN ON-LINE PLATFORM TO CONNECT VOLUNTEERS AND CLINICAL RESEARCHERS S Pratap; L Byrne; PA Harris Meharry Medical College (SP), Vanderbilt University (LB, PAH) Addressing Health Disparities: Translational Research Center (MeTRC) The Role of Translational Research #MeharryTRC | November 10–11, 2016 | Nashville, Tennessee NOTES ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... NOTES ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................... Funding for this conference was made possible [in part] by Grant Number 5U54MD007593-08 from the National Institute on Minority Health and Health Disparities (NIMHD) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the NIH; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. The current MeTRC grant supports health disparities and translational research on HIV/AIDS, cancer, cardiovascular diseases, diabetes, and neurological disorders. www.MeTRCconference.com
© Copyright 2026 Paperzz